Open-label, randomized, non-inferiority clinical trial of artesunate-amodiaquine versus artemether-lumefantrine fixed-dose combinations in children and adults with uncomplicated falciparum malaria in Côte d'Ivoire

BACKGROUND: Emergence of artemisinin resistance has raised concerns that the most potent anti-malarial drug may be under threat. Artesunate-amodiaquine (AS-AQ) and artemether-lumefantrine (AL) are, respectively, the first- and second-line treatments for uncomplicated falciparum malaria in Côte d’Ivo...

全面介紹

Na minha lista:
書目詳細資料
發表在:Malar J
Main Authors: Toure, Offianan A, Assi, Serge B, N’Guessan, Tiacoh L, Adji, Gbessi E, Ako, Aristide B, Brou, Marie J, Ehouman, Marie F, Gnamien, Laeticia A, Coulibaly, M’Lanhoro AA, Coulibaly, Baba, Beourou, Sylvain, Bassinka, Issiaka, Soumahoro, Adama, Kadjo, Florence, Tano, Mea A
格式: Artigo
語言:Inglês
出版: BioMed Central 2014
主題:
Research
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC4251865/
https://ncbi.nlm.nih.gov/pubmed/25409546
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1475-2875-13-439
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍